Although MEK and AKT inhibitors should overcome these resistance mechanisms, some of the alterations mentioned above were found in the context of BRAF/MEK dual inhibition, indicating that, in some modalities, targeting downstream pathways is not sufficient to halt tumor growth. The gene discussed is MAP2K7; the disease is neoplasm.